Datapoint: Enhertu Snags Key HER2-Mutant Lung Cancer Approval

With its latest FDA nod, AstraZeneca and Daiichi Sankyo’s Enhertu is now the first available drug that specifically targets HER2-mutant non-small cell lung cancer (NSCLC). It will be available to adult patients who have previously received another systemic therapy. Enhertu was first approved to treat HER2-positive metastatic breast cancer in October 2019, an indication for which it currently holds covered or better status for 62% of all insured lives under the pharmacy benefit. 78% of lives have covered or better access to Enhertu under the medical benefit.

SOURCE: MMIT Analytics, as of 8/22/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today